Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Rowell

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Immunity|January 16, 2009
Programming perpetual T helper cell plasticityEmily Rowell, Christopher B Wilson
Current Opinion in Immunology|May 20, 2008
Long-range regulation of cytokine gene expressionEmily Rowell, Matthias Merkenschlager, Christopher B Wilson
Nature Reviews. Immunology|January 20, 2009
Epigenetic control of T-helper-cell differentiationChristopher B Wilson, Emily Rowell, Masayuki Sekimata
Communications Biology|January 9, 2021
A biomimetic assay platform for the interrogation of antigen-dependent anti-tumor T-cell functionJeremy To, Doug Quackenbush, Emily Rowell, et al.
Communications Biology|August 28, 2021
Retraction Note: A biomimetic assay platform for the interrogation of antigen-dependent anti-tumor T-cell functionJeremy To, Doug Quackenbush, Emily Rowell, et al.
Cell Host & Microbe|August 17, 2010
Fidelity of pathogen-specific CD4+ T cells to the Th1 lineage is controlled by exogenous cytokines, interferon-gamma expression, and pathogen lifestyleMeredith M Curtis, Emily Rowell, Shahin Shafiani, et al.
Journal for Immunotherapy of Cancer|January 18, 2023
INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responsesFlorian J Sulzmaier, Nadja Kern, Sae Jeong Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in ChondrosarcomaVivek Subbiah, Sant P Chawla, Anthony P Conley, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Immunity|January 16, 2009
Programming perpetual T helper cell plasticityEmily Rowell, Christopher B Wilson
Current Opinion in Immunology|May 20, 2008
Long-range regulation of cytokine gene expressionEmily Rowell, Matthias Merkenschlager, Christopher B Wilson
Nature Reviews. Immunology|January 20, 2009
Epigenetic control of T-helper-cell differentiationChristopher B Wilson, Emily Rowell, Masayuki Sekimata
Communications Biology|January 9, 2021
A biomimetic assay platform for the interrogation of antigen-dependent anti-tumor T-cell functionJeremy To, Doug Quackenbush, Emily Rowell, et al.
Communications Biology|August 28, 2021
Retraction Note: A biomimetic assay platform for the interrogation of antigen-dependent anti-tumor T-cell functionJeremy To, Doug Quackenbush, Emily Rowell, et al.
Cell Host & Microbe|August 17, 2010
Fidelity of pathogen-specific CD4+ T cells to the Th1 lineage is controlled by exogenous cytokines, interferon-gamma expression, and pathogen lifestyleMeredith M Curtis, Emily Rowell, Shahin Shafiani, et al.
Journal for Immunotherapy of Cancer|January 18, 2023
INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responsesFlorian J Sulzmaier, Nadja Kern, Sae Jeong Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in ChondrosarcomaVivek Subbiah, Sant P Chawla, Anthony P Conley, et al.
Pageof 1